Inhibition of catechol‐O‐methyltransferase contributes to more stable levodopa plasma levels
Identifieur interne : 003379 ( Main/Exploration ); précédent : 003378; suivant : 003380Inhibition of catechol‐O‐methyltransferase contributes to more stable levodopa plasma levels
Auteurs : Thomas Müller [Allemagne] ; Christoph Erdmann [Allemagne] ; Siegfried Muhlack [Allemagne] ; Dirk Bremen [Allemagne] ; Horst Przuntek [Allemagne] ; Dirk Woitalla [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-03.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacology), Carbidopa (blood), Carbidopa (therapeutic use), Catechol O-Methyltransferase Inhibitors, Catechol O-methyltransferase, Catechols (administration & dosage), Catechols (pharmacology), Dopamine Agonists (blood), Dopamine Agonists (therapeutic use), Drug Combinations, Drug Therapy, Combination, Entacapone, Female, Humans, Levodopa, Levodopa (blood), Levodopa (pharmacology), Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Nitriles, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, entacapone, levodopa.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Catechols.
- chemical , blood : Carbidopa, Dopamine Agonists, Levodopa.
- chemical , pharmacology : Antiparkinson Agents, Catechols, Levodopa.
- chemical , therapeutic use : Carbidopa, Dopamine Agonists, Levodopa.
- drug therapy : Parkinson Disease.
- Adult, Aged, Catechol O-Methyltransferase Inhibitors, Drug Combinations, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Nitriles.
Abstract
The short plasma half‐life limits the antiparkinsonian efficacy of levodopa/carbidopa (LD/CD). Administration of LD/CD with the catechol‐O‐methyltransferase inhibitor entacapone in one tablet (LCE) may extend plasma half‐life of LD and thus its effect on motor symptoms in patients with Parkinson's disease (PD). The objectives of this study were to monitor the motor response to a switch from LD/CD to LCE by a simultaneous performance of an instrumental motor test and rating of motor symptoms and to compare the LD plasma behavior between both conditions in terms of stability. Twenty‐one treated PD patients received LD/CD and then the identical oral LD dosage of LCE within a standardized setting on 2 consecutive days. Rating better reflected the motor improvement after LD application than the instrumental test. Motor symptoms of PD patients decreased significantly more during the LCE than the LD/CD condition, probably due to significantly higher LD plasma levels and a significantly less pronounced fall of the LD concentrations following the second LD intake. Our study shows a more stable LD plasma behavior during LCE intake and accordingly a better effect on motor symptoms according to rating outcomes and motor test results to a lesser extent. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20717
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001E71
- to stream Istex, to step Curation: 001E71
- to stream Istex, to step Checkpoint: 001E38
- to stream PubMed, to step Corpus: 002E57
- to stream PubMed, to step Curation: 002E57
- to stream PubMed, to step Checkpoint: 002C70
- to stream Ncbi, to step Merge: 001471
- to stream Ncbi, to step Curation: 001471
- to stream Ncbi, to step Checkpoint: 001471
- to stream Main, to step Merge: 004692
- to stream PascalFrancis, to step Corpus: 001C04
- to stream PascalFrancis, to step Curation: 001117
- to stream PascalFrancis, to step Checkpoint: 001A51
- to stream Main, to step Merge: 004B46
- to stream Main, to step Curation: 003379
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibition of catechol‐O‐methyltransferase contributes to more stable levodopa plasma levels</title><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></author><author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name></author><author><name sortKey="Muhlack, Siegfried" sort="Muhlack, Siegfried" uniqKey="Muhlack S" first="Siegfried" last="Muhlack">Siegfried Muhlack</name></author><author><name sortKey="Bremen, Dirk" sort="Bremen, Dirk" uniqKey="Bremen D" first="Dirk" last="Bremen">Dirk Bremen</name></author><author><name sortKey="Przuntek, Horst" sort="Przuntek, Horst" uniqKey="Przuntek H" first="Horst" last="Przuntek">Horst Przuntek</name></author><author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6A10A340976F2C2E86A37FA1E53AE43E2EE8FF53</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20717</idno><idno type="url">https://api.istex.fr/document/6A10A340976F2C2E86A37FA1E53AE43E2EE8FF53/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E71</idno><idno type="wicri:Area/Istex/Curation">001E71</idno><idno type="wicri:Area/Istex/Checkpoint">001E38</idno><idno type="wicri:doubleKey">0885-3185:2006:Muller T:inhibition:of:catechol</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16211593</idno><idno type="wicri:Area/PubMed/Corpus">002E57</idno><idno type="wicri:Area/PubMed/Curation">002E57</idno><idno type="wicri:Area/PubMed/Checkpoint">002C70</idno><idno type="wicri:Area/Ncbi/Merge">001471</idno><idno type="wicri:Area/Ncbi/Curation">001471</idno><idno type="wicri:Area/Ncbi/Checkpoint">001471</idno><idno type="wicri:doubleKey">0885-3185:2006:Muller T:inhibition:of:catechol</idno><idno type="wicri:Area/Main/Merge">004692</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0208440</idno><idno type="wicri:Area/PascalFrancis/Corpus">001C04</idno><idno type="wicri:Area/PascalFrancis/Curation">001117</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001A51</idno><idno type="wicri:doubleKey">0885-3185:2006:Muller T:inhibition:of:catechol</idno><idno type="wicri:Area/Main/Merge">004B46</idno><idno type="wicri:Area/Main/Curation">003379</idno><idno type="wicri:Area/Main/Exploration">003379</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Inhibition of catechol‐O‐methyltransferase contributes to more stable levodopa plasma levels</title><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author><author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author><author><name sortKey="Muhlack, Siegfried" sort="Muhlack, Siegfried" uniqKey="Muhlack S" first="Siegfried" last="Muhlack">Siegfried Muhlack</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author><author><name sortKey="Bremen, Dirk" sort="Bremen, Dirk" uniqKey="Bremen D" first="Dirk" last="Bremen">Dirk Bremen</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Orion Pharma GmbH, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Przuntek, Horst" sort="Przuntek, Horst" uniqKey="Przuntek H" first="Horst" last="Przuntek">Horst Przuntek</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author><author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-03">2006-03</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="332">332</biblScope><biblScope unit="page" to="336">336</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6A10A340976F2C2E86A37FA1E53AE43E2EE8FF53</idno><idno type="DOI">10.1002/mds.20717</idno><idno type="ArticleID">MDS20717</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (pharmacology)</term><term>Carbidopa (blood)</term><term>Carbidopa (therapeutic use)</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Catechol O-methyltransferase</term><term>Catechols (administration & dosage)</term><term>Catechols (pharmacology)</term><term>Dopamine Agonists (blood)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Combinations</term><term>Drug Therapy, Combination</term><term>Entacapone</term><term>Female</term><term>Humans</term><term>Levodopa</term><term>Levodopa (blood)</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Nitriles</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>entacapone</term><term>levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Carbidopa</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Carbidopa</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Drug Combinations</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Nitriles</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Catechol O-methyltransferase</term><term>Entacapone</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The short plasma half‐life limits the antiparkinsonian efficacy of levodopa/carbidopa (LD/CD). Administration of LD/CD with the catechol‐O‐methyltransferase inhibitor entacapone in one tablet (LCE) may extend plasma half‐life of LD and thus its effect on motor symptoms in patients with Parkinson's disease (PD). The objectives of this study were to monitor the motor response to a switch from LD/CD to LCE by a simultaneous performance of an instrumental motor test and rating of motor symptoms and to compare the LD plasma behavior between both conditions in terms of stability. Twenty‐one treated PD patients received LD/CD and then the identical oral LD dosage of LCE within a standardized setting on 2 consecutive days. Rating better reflected the motor improvement after LD application than the instrumental test. Motor symptoms of PD patients decreased significantly more during the LCE than the LD/CD condition, probably due to significantly higher LD plasma levels and a significantly less pronounced fall of the LD concentrations following the second LD intake. Our study shows a more stable LD plasma behavior during LCE intake and accordingly a better effect on motor symptoms according to rating outcomes and motor test results to a lesser extent. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Hambourg</li></region><settlement><li>Hambourg</li></settlement></list><tree><country name="Allemagne"><noRegion><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></noRegion><name sortKey="Bremen, Dirk" sort="Bremen, Dirk" uniqKey="Bremen D" first="Dirk" last="Bremen">Dirk Bremen</name><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name><name sortKey="Muhlack, Siegfried" sort="Muhlack, Siegfried" uniqKey="Muhlack S" first="Siegfried" last="Muhlack">Siegfried Muhlack</name><name sortKey="Przuntek, Horst" sort="Przuntek, Horst" uniqKey="Przuntek H" first="Horst" last="Przuntek">Horst Przuntek</name><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003379 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003379 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6A10A340976F2C2E86A37FA1E53AE43E2EE8FF53
|texte= Inhibition of catechol‐O‐methyltransferase contributes to more stable levodopa plasma levels
}}
| This area was generated with Dilib version V0.6.23. |  |